(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that results from the Phase I L-DOS47 study will be presented at the upcoming 9th International Conference of Contemporary Oncology meeting in Poznan, Poland from the 22nd to the 24th of March, 2017. The leading theme of the conference is genome-based precision oncology – direct targeting and immune-targeting of cancer.
- 0 Comments
- Conference presentations